The content on this site is intended for healthcare professionals only
Prof Cmelak talks to ecancertv at ASCO 2014 about the findings of an NIH-funded phase II study which suggest that certain patients with human papilloma virus (HPV)-positive oropharyngeal cancer can safely receive lower- dose radiation therapy, using a new approach that customises radiation dose based on response to induction chemotherapy and other prognostic factors.
ecancer's filming at ASCO has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ASCO 2024: Lung cancer highlights
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
Gynaecological cancer: New targets and immunotherapy developments
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
The TARGIT-A randomised trial: TARGIT-IORT versus whole breast radiation therapy: long-term local control and survival
Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer
Overview of the management of HER2-low breast cancer patients
